Pancreatic Adenocarcinoma Signature Stratification for Treatment

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Conditions: Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer
Interventions: Drug: Folfirinox; Drug: Gemcitabine/nab-paclitaxel
Sponsors: University Health Network, Toronto; Johns Hopkins University; Cold Spring Harbor Laboratory; Ontario Institute for Cancer Research; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Stand Up To Cancer
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments